Literature DB >> 23783642

Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.

Alvin A Holder1, Patrick Taylor, Anthony R Magnusen, Erick T Moffett, Kyle Meyer, Yiling Hong, Stuart E Ramsdale, Michelle Gordon, Javelyn Stubbs, Luke A Seymour, Dhiraj Acharya, Ralph T Weber, Paul F Smith, G Charles Dismukes, Ping Ji, Laura Menocal, Fengwei Bai, Jennie L Williams, Donald M Cropek, William L Jarrett.   

Abstract

We report the synthesis and characterisation of mixed-class="Chemical">metal binuclear pan class="Chemical">ruthenium(II)-vanadium(IV) complexes, which were used as potential photodynamic therapeutic agents for melanoma cell growth inhibition. The novel complexes, [Ru(pbt)2(phen2DTT)](PF6)2·1.5H2O 1 (where phen2DTT = 1,4-bis(1,10-phenanthrolin-5-ylsulfanyl)butane-2,3-diol and pbt = 2-(2'-pyridyl)benzothiazole) and [Ru(pbt)2(tpphz)](PF6)2·3H2O 2 (where tpphz = tetrapyrido[3,2-a:2',3'-c:3'',2''-h:2''',3'''-j]phenazine) were synthesised and characterised. Compound 1 was reacted with [VO(sal-L-tryp)(H2O)] (where sal-L-tryp = N-salicylidene-L-tryptophanate) to produce [Ru(pbt)2(phen2DTT)VO(sal-L-tryp)](PF6)2·5H2O 4; while [VO(sal-L-tryp)(H2O)] was reacted with compound 2 to produce [Ru(pbt)2(tpphz)VO(sal-L-tryp)](PF6)2·6H2O 3. All complexes were characterised by elemental analysis, HRMS, ESI MS, UV-visible absorption, ESR spectroscopy, and cyclic voltammetry, where appropriate. In vitro cell toxicity studies (with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay) via dark and light reaction conditions were carried out with sodium diaqua-4,4',4'',4''' tetrasulfophthalocyaninecobaltate(II) (Na4[Co(tspc)(H2O)2]), [VO(sal-L-tryp)(phen)H2O, and the chloride salts of complexes 3 and 4. Such studies involved A431, human epidermoid carcinoma cells; human amelanotic malignant melanoma cells; and HFF, non-cancerous human skin fibroblast cells. Both chloride salts of complexes 3 and 4 were found to be more toxic to melanoma cells than to non-cancerous fibroblast cells, and preferentially led to apoptosis of the melanoma cells over non-cancerous skin cells. The anti-cancer property of the chloride salts of complexes 3 and 4 was further enhanced when treated cells were exposed to light, while no such effect was observed on non-cancerous skin fibroblast cells. ESR and (51)V NMR spectroscopic studies were also used to assess the stability of the chloride salts of complexes 3 and 4 in aqueous media at pH 7.19. This research illustrates the potential for using mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes to fight skin cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23783642      PMCID: PMC3751419          DOI: 10.1039/c3dt50547b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  59 in total

Review 1.  The history of photodetection and photodynamic therapy.

Authors:  R Ackroyd; C Kelty; N Brown; M Reed
Journal:  Photochem Photobiol       Date:  2001-11       Impact factor: 3.421

2.  DNA cleavage by photogenerated Rh(2)(O(2)CCH(3))(4)(H(2)O)(2)(+).

Authors:  P K Fu; P M Bradley; C Turro
Journal:  Inorg Chem       Date:  2001-05-21       Impact factor: 5.165

3.  New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.

Authors:  Barry D Liboiron; Katherine H Thompson; Graeme R Hanson; Edmond Lam; Nicolas Aebischer; Chris Orvig
Journal:  J Am Chem Soc       Date:  2005-04-13       Impact factor: 15.419

4.  Is the spin-orbit coupling important in the prediction of the 51V hyperfine coupling constants of V(IV) O2+ species? ORCA versus Gaussian performance and biological applications.

Authors:  Giovanni Micera; Eugenio Garribba
Journal:  J Comput Chem       Date:  2011-07-06       Impact factor: 3.376

5.  Synthesis, characterization, and preliminary in vitro studies of vanadium(IV) complexes with a Schiff base and thiosemicarbazones as mixed-ligands.

Authors:  Nerissa A Lewis; Fange Liu; Luke Seymour; Anthony Magnusen; Travis R Erves; Jessa Faye Arca; Floyd A Beckford; Ramaiyer Venkatraman; Antonio González-Sarrías; Frank R Fronczek; Don G Vanderveer; Navindra P Seeram; Aimin Liu; William L Jarrett; Alvin A Holder
Journal:  Eur J Inorg Chem       Date:  2012-02-01       Impact factor: 2.524

6.  Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window.

Authors:  Erin Wachter; David K Heidary; Brock S Howerton; Sean Parkin; Edith C Glazer
Journal:  Chem Commun (Camb)       Date:  2012-10-07       Impact factor: 6.222

7.  A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: synthesis, characterization, DNA binding, and melanoma cell studies.

Authors:  Sandya Rani-Beeram; Kyle Meyer; Anna McCrate; Yiling Hong; Mark Nielsen; Shawn Swavey
Journal:  Inorg Chem       Date:  2008-12-01       Impact factor: 5.165

8.  Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats.

Authors:  Ming Li; Wenjun Ding; Jason J Smee; Bharat Baruah; Gail R Willsky; Debbie C Crans
Journal:  Biometals       Date:  2009-12       Impact factor: 2.949

Review 9.  Vanadium in cancer treatment.

Authors:  Angelos M Evangelou
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

10.  Phthalocyanines covalently bound to biomolecules for a targeted photodynamic therapy.

Authors:  Jean-Philippe Taquet; Céline Frochot; Vincent Manneville; Muriel Barberi-Heyob
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

View more
  1 in total

1.  Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.

Authors:  Myrna Hurtado; Umesh T Sankpal; Aboubacar Kaba; Shahela Mahammad; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Cell Physiol Biochem       Date:  2018-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.